Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

Sony unveils new ‘Project Field’ device

At a press conference held in Tokyo on Wednesday, Sony’s Kazuyuki Sakamoto unveiled the company’s new hardware --- a sleek and lightweight device called ‘Project Field,’ which has the capability to connect to real-world objects for use in controlling games on mobile devices.

Project Field is a toys-to-life product which has been...

Most Popular

2% of Washington D.C. population HIV infected: CDC

Pointing to the growing HIV/AIDS crisis, the Centers for...

Rochester Optical starts offering prescription lenses for Snap Spectacles

On Thursday, lens manufacturer Rochester Optical said...

Researchers find new way to treat prostate cancer

Suggesting a new method to fight back the growing...

Altice USA intends to replace cable with fiber-to-the-home technology

On Wednesday, Altice USA -- the fourth-ranking cable...

Poll

Can Greece Come out of Economic Problems: